Amosulalol - Astellas Pharma/LTL Pharma

Drug Profile

Amosulalol - Astellas Pharma/LTL Pharma

Alternative Names: Lowgan; LY 137224; YM 09538

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; LTL Pharma
  • Class Antihypertensives; Ethanolamines; Small molecules
  • Mechanism of Action Alpha beta adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 05 Jul 1999 No-Development-Reported for Hypertension in South Korea (PO)
  • 05 Jul 1999 No-Development-Reported for Hypertension in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top